**Supplementary table 2.** Results of ClinicalTrial.gov registry search.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Trial number** | **Title of trial** | **Sponsor** | **Start date** | **Status** | **Reported outcome** |
| NCT01222468 | A Randomized Double-Blinded Crossover Trial Assessing the Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons | University of Manitoba | June 2012 | Completed Feb 2015 | Not reported |
| NCT01429181 | Pilot Study to Evaluate Efficacy, Tolerability and Safety Nonracemic Methadone HCl in Patients With Chronic Peripheral Neuropathic Pain: Double-Blind, Placebo-Controlled, Crossover Study Followed by Open-Label, Single-Arm Extension | MetaPharm, Inc. | January 2012 | Completed December 2014 | Not reported |
| NCT01463397 | Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain | Sanofi | March 2012 | Completed May 2013 | Not reported |
| NCT01485094 | Evaluation of the Efficacy, Tolerability, and Safety of 7 Days of Treatment With GRT6010 or Pregabalin in Comparison to Placebo in Subjects With Peripheral Neuropathic Pain | Grünenthal GmbH | February 2012 | Terminated Jan 2013 | It was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis. |
| NCT01536314 | Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration | University Hospital, Clermont-Ferrand | February 2012 | Completed November 2013 | Primary efficacy analysis: statistically significant difference to placebo1 |
| NCT01540630 | A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia | Biogen | March 31, 2012 | Completed June 30, 2014 | Primary efficacy endpoint: no statistically significant difference to placebo2 |
| NCT01544296 | Phase II Study of KHK6188 (A Placebo-controlled, Double Blind, Crossover Study of KHK6188 in Postherpetic Neuralgia) | Kyowa Kirin Co., Ltd. | February 2012 | Completed June 2013 | Not reported |
| NCT01555983 | The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury | University of California, Davis | July 2012 | Completed August 2014 | Primary efficacy endpoint: statistically significant difference to placebo |
| NCT01557010 | The Clinical Trial for Evaluation of Efficacy and Safety of DWP05195 in Postherpetic Neuralgia: Double-blind, Placebo-controlled, Randomized, Multi-center, Exploratory Clinical Trial | Daewoong Pharmaceutical Co. LTD | March 2012 | Completed Dec 2013 | Not reported |
| NCT01579279 | A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain | AbbVie (prior sponsor, Abbott) | April 2012 | Terminated May 2012 | Not reported |
| NCT01582646 | Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain | University Hospital, Strasbourg, France | January 2012 | Terminated September 2017 | Recruitment difficulties |
| NCT01588314 | Placebo Controlled Trial Evaluating Gabapentin for the Treatment of Small Fiber Neuropathic Pain in Patients With Fabry Disease | University of Minnesota | April 2012 | Withdrawn: June 2014 | No patients were enrolled. No data & no study results to report. |
| NCT01602185 | Antagonists NMDA in Relay to Ketamine in Neuropathic Pain | University Hospital, Clermont-Ferrand | May 2012 | Completed September 7, 2016 | Not reported |
| NCT01633086 | A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy | China Medical University Hospital | July 2012 | Completed Feb 2013 | Not reported |
| NCT01655823 | A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain | Wex Pharmaceuticals Inc. | July 2012 | Terminated (Interim analysis completed and decided to terminate and proceed to Phase 3 trial.)  February 11, 2015 | No statistical analysis provided |
| NCT01655849 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Z160 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | Zalicus | August 2012 | Completed Nov 2013 | Not reported |
| NCT01678924 | A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia | Allergan | January 2013 | Terminated Sept 2015 | No p values included in results |
| NCT01688947 | A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) | Purdue Pharma LP | September 2012 | Completed April 2014 | Not reported |
| NCT01699854 | Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy | Rigshospitalet, Denmark | August 2012 | Terminated (Expiration of the placebo patch)  September 2013 | Primary efficacy endpoint: no statistically significant difference to placebo3 |
| NCT01701362 | A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain | Viatris Inc. | October 2012 | Completed August 2015 | Primary efficacy analysis: no statistically significant difference to placebo4 |
| NCT01726413 | A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy | Glenmark Pharmaceuticals Ltd. India | November 2012 | Completed September 2014 | Primary efficacy analysis: no statistically significant difference to placebo in the overall population but in a subpopulation5 |
| NCT01748695 | A Phase IIa, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study Evaluating the Safety, Tolerability and Efficacy of V158866 in Central Neuropathic Pain Following Spinal Cord Injury | Brigham and Women's Hospital | June 2013 | Completed July 2015 | Primary efficacy analysis: no statistically significant difference to placebo |
| NCT01748877 | A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN) | NeurAxon Inc. | January 2013 | Completed June 2014 | Not reported |
| NCT01752322 | Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain | Grünenthal GmbH | October 2012 | Completed June 2016 | Primary efficacy endpoint: no statistically significant difference to placebo6 |
| NCT01757873 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Z160 in Subjects With Postherpetic Neuralgia | Zalicus | December 2012 | Completed Nov 2013 | Not reported |
| NCT01848730 | A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia | Convergence Pharmaceuticals | April 2013 | Completed May 2014 | Not reported |
| NCT01855594 | Double Blind, Randomized Placebo-controlled Clinical Study Evaluating the Efficacy of Lithium Carbonate in the Treatment of Neuropathic Pain of Patients With Spinal Cord Injury | China Spinal Cord Injury Network | May 2013 | Completed June 2015 | Not reported |
| NCT01863810 | Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain | KunWha Pharmaceutical Co., Ltd. | August 2013 | Unknown | Not reported |
| NCT01869569 | Effect of Pregabalin in Patients With Radiotherapy-Related Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled Trial | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | February 2013 | Completed January 2017 | Primary efficacy analysis: statistically significant difference to placebo7 |
| NCT01886313 | A DOUBLE BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP EVALUATION OF CIVAMIDE (ZUCAPSAICIN) 0.01% AND VEHICLE NASAL SPRAYS IN THE TREATMENT OF POSTHERPETIC NEURALGIA OF THE TRIGEMINAL NERVE | Winston Laboratories | March 2014 | Terminated April 2015 | No p values included in results |
| NCT01911377 | The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis | University of Manitoba | October 2013 | Terminated  August 2015 | 12 SCI volunteers completed the study. As the data analysis was negative, the decision was made not to proceed with MS recruitment. |
| NCT01920087 | Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders | Allodynic Therapeutics, LLC | March 2014 | Withdrawn | N/A |
| NCT01928849 | Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain | Duke University | December 2013 | Completed September 26, 2017 | Primary efficacy endpoint: no statistically significant difference to placebo |
| NCT01951911 | Low-dose Ketamine as Adjuvant Treatment to Morphine in Neuropathic Cancer Pain | Haukeland University Hospital | September 2013 | Withdrawn (Poor patient recruitment.)  Oct 2016 | N/A |
| NCT02065349 | A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain | Astellas Pharma Europe B.V. | February 24, 2014 | Completed February 13, 2015 | Only reported in EudraCT  Primary efficacy endpoint: no statistically significant difference to placebo |
| NCT02088632 | A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia | Thomas Jefferson University | March 14, 2014 | Terminated October 19, 2016 | Unable to enrolled in a timely manner  Results submitted but not yet posted |
| NCT02100956 | Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain | Wake Forest University Health Sciences | June 19, 2014 | Recruiting | N/A |
| NCT02137954 | Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study. | Assistance Publique Hopitaux De Marseille | May 2014 | Unknown | Not reported |
| NCT02217267 | Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study | Mahidol University | August 1, 2014 | Completed Feb 2018 | Not reported |
| NCT02240199 | Pregabalin and Lidocaine in Breast Cancer Surgery to Alter Neuropathic Pain (PLAN): A Pilot Trial | McMaster University | November 2014 | Completed Jan 2016 | Feasibility trial8 |
| NCT02283957 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) | Centrexion Therapeutics | October 2014 | Completed June 2016 | Not reported |
| NCT02318706 | An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension | Daiichi Sankyo Co., Ltd. | January 2015 | Completed June 29, 2017 | Primary efficacy analysis: the highest dose tested (30 mg) is statistically significantly different to placebo9 |
| NCT02328911 | Laser Therapy Treatment of Peripheral Neuropathic Pain in Individuals With Diabetes | University of Miami | January 2015 | Withdrawn (Difficulty recruiting qualified subjects.)  August 2015 | N/A |
| NCT02336529 | Tenderpoint and Ultrasound Guided Nerveblocks for Persistent Pain After Breast Cancer Surgery | Rigshospitalet, Denmark | July 2016 | Unknown | Not reported |
| NCT02345291 | A Phase 2a, Randomized, Double-blind, Placebo (Vehicle)-Controlled, Dose Finding Trial to Assess the Safety, Tolerability and Efficacy of NRD135S.E1 in Patients With Neuropathic Pain Associated With Diabetes Mellitus | Novaremed Ltd. | April 2015 | Completed July 2016 | Result submitted but not yet posted |
| NCT02365636 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia. | Teva Branded Pharmaceutical Products R&D, Inc. | February 26, 2015 | Completed May 9, 2017 | Primary efficacy endpoint: no statistically significant difference to placebo |
| NCT02412852 | A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP) | TheraVasc Inc. | April 28, 2015 | Completed April 3, 2017 | Primary outcome safety |
| NCT02426411 | A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Two Dose Levels of EMA401 in Patients With Postherpetic Neuralgia | Spinifex Pharmaceuticals Pty Ltd | June 2015 | Withdrawn | 0 participants |
| NCT02460692 | A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain | University of California, San Diego | December 2016 | Completed March 25, 2020 | Not reported |
| NCT02467517 | Ketamine and Neuropathic Pain | University Hospital, Clermont-Ferrand | November 2015 | Unknown | Not reported |
| NCT02473016 | A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia | Capnia, Inc. | September 2015 | Completed April 2017 | Not reported |
| NCT02484170 | Mannitol Cream in the Treatment of Post-herpetic Neuralgia; a Randomized Placebo-Controlled Crossover Pilot Study | University of British Columbia | September 30, 2015 | Completed April 30, 2017 | Not reported |
| NCT02490436 | A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain | Sorlandet Hospital HF | October 2015 | Completed Oct 2016 | Proof-of-concept trial. No statistical evidence of efficacy10 |
| NCT02597257 | Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain: Randomized, Controlled, Comparative Study | Seoul National University Hospital | August 2015 | Unknown | Not reported |
| NCT02601586 | Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial | University Hospital, Toulouse | September 2016 | Recruiting | N/A |
| NCT02607254 | Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy | Johns Hopkins University | September 2015 | Completed July 2018 | No statistical analysis |
| NCT02673866 | A Randomized Double-Blind Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) | Daiichi Sankyo, Inc. | February 2016 | Withdrawn Jan 2017 | Reassessment of phase 2 study indication |
| NCT02701374 | TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia -Double Blind Comparison With Placebo- | Toray Industries, Inc | March 2016 | Completed July 2017 | Not reported |
| NCT02736890 | Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury | Icahn School of Medicine at Mount Sinai | March 2016 | Terminated (funding not available to continue)  July 17, 2018 | No statistical analysis |
| NCT02763592 | Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery | University Hospital, Clermont-Ferrand | May 2016 | Completed April 2017 | Primary efficacy endpoint: statistically significant difference to placebo11 |
| NCT02868801 | Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia -A Multicenter,Randomized, Double-blind, Placebo-controlled Trial | Jiangsu HengRui Medicine Co., Ltd. | March 2015 | Unknown | Not reported |
| NCT02924675 | Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer | University Hospital, Lille | June 5, 2015 | Terminated (not sufficiency recruitment)  December 12, 2018 | Not reported |
| NCT02935608 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | Biogen | October 31, 2016 | Completed August 6, 2018 | Only reported on EudraCT  Primary efficacy endpoint: no statistically significant difference to placebo |
| NCT02957851 | Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) for the Treatment of Peripheral Neuropathic Pain: A Randomises, International, Multicentre, Placebo-Controlled, Phenotype-stratified Phase IIa Study | Air Liquide Santé International | November 2016 | Completed August 2018 | Primary efficacy analysis: no statistically significant difference to placebo12 |
| NCT03009500 | A Multi-center Randomized Controlled Trial of Efficacy and Safety of Perineural Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain: The Resperist Study | University Health Network, Toronto | January 2017 | Completed June 2019 | Not reported |
| NCT03063931 | Effect of the Oral Route of Magnesium on Pre and Post-mastectomy on the Post-surgery Pain | University Hospital, Clermont-Ferrand | March 2017 | Unknown | Not reported |
| NCT03094195 | A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia | Novartis Pharmaceuticals | June 27, 2017 | Terminated early due to pre-clinical toxicity data that became available after start of trial  March 7, 2019 | Primary efficacy endpoint: no statistically significant difference to placebo13 |
| NCT03113448 | 0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial | Thammasat University | January 19, 2017 | Completed January 31, 2018 | Not reported |
| NCT03158376 | Perioperative Gabapentin for Chronic Post-thoracotomy Pain: a Randomized, Double Blind, Placebo-controlled Study. | University Hospital, Lille | September 2015 | Unknown | Not reported |
| NCT03176472 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy | Regenacy Pharmaceuticals LLC | December 7, 2020 | Recruiting | N/A |
| NCT03201393 | A Single Site, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of Low-Dose Naltrexone and Acetaminophen Combination vs. Placebo in the Treatment of Chronic Low Back Pain (ANODYNE-4) | Allodynic Therapeutics, LLC | August 15, 2017 | Completed July 26, 2018 | Not reported |
| NCT03202979 | Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Pilot Study. | Aziende Chimiche Riunite Angelini Francesco S.p.A | May 16, 2017 | Completed August 9, 2018 | Primary efficacy endpoint: no statistically significant difference to placebo14 |
| NCT03219320 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Aptinyx | June 27, 2017 | Completed November 2, 2018 | No p values for primary efficacy analysis included in results |
| NCT03240783 | A Comparative Effectiveness Randomised Placebo Controlled Pilot Trial of the Management of Acute Lumbar Radicular Pain: Evaluate Route Versus Pharmacology of Intervention, and Feasibility in Public Hospital and Community Practice Settings. | St George Hospital, Australia | July 8, 2017 | Unknown | Not reported |
| NCT03254394 | Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN) | Washington University School of Medicine | September 15, 2017 | Active, not recruiting | Results submitted |
| NCT03297294 | A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Painful Diabetic Neuropathy (EMPADINE) | Novartis Pharmaceuticals | March 14, 2018 | Terminated due to animal toxicity data | Primary efficacy endpoint: no statistically significant difference to placebo13 |
| NCT03324035 | Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study | University of Sao Paulo | March 1, 2017 | Active, not recruiting | Not reported |
| NCT03342950 | The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain | Research Institute of the McGill University Health Centre | February 19, 2019 | Terminated October 12, 2021 | Low recruitment due to the COVID-19 pandemic |
| NCT03513822 | Ketamine's Efficiency in the Treatment of Chronic Pain With an Added Inflammatory Component Exploring the Kynurenin Pathway. A Randomized, Double Blind, Placebo-controlled Trial | Redar | February 16, 2018 | Unknown | Not reported |
| NCT03555916 | Use of Botulinum Toxin (BTX) for the Treatment of Peripheral Painful Traumatic Trigeminal Neuropathy (PPTTN) | Assistance Publique - Hôpitaux de Paris | April 4, 2019 | Recruiting | N/A |
| NCT03559985 | Analgesic Effect of Paracetamol in Neuropathic Pain Patients | University Hospital, Clermont-Ferrand | August 20, 2018 | Unknown | Not reported |
| NCT03663101 | A Double-blind, Randomised, Placebo Controlled, Proof-of-concept Study in Subjects With Abdominal or Thoracic Chronic Scar Pain to Assess the Analgesic Properties of Intradermal Doses of Dysport® | Ipsen | October 30, 2018 | Completed November 8, 2019 | No statistical analyses for primary efficacy endpoints provided |
| NCT03664921 | A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy | Syntrix Biosystems, Inc. | November 15, 2018 | Completed August 17, 2020 | Not reported |
| NCT03747562 | Multi-centre, Double-blind, Randomized-controlled Trial to Study the Efficacy and Safety of Gabapentin to Reduce Strong Opioid Use in Treatment of Radiation-induced Pain in Head and Neck Cancer Patients During Curative Radio(Chemo)Therapy | University Hospital, Ghent | March 1, 2019 | Unknown | Not reported |
| NCT03749642 | Efficacy and Safety of Fixed-Dose Combination (FDC) Products Containing Trazodone and Gabapentin in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose Finding Study. | Aziende Chimiche Riunite Angelini Francesco S.p.A | November 22, 2018 | Completed June 6, 2020 | Only reported on EudraCT  Primary efficacy endpoint: no statistically significant difference to placebo |
| NCT03773055 | A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 in Patients With Neuropathic Pain in Cancer | Nobelpharma | April 3, 2019 | Terminated (Low recruitment)  September 30, 2020 | Not reported |
| NCT03777956 | The Effect of Lacosamide in Peripheral Neuropathic Pain: a Randomized, Double-blind, Placebo Controlled, Phenotype-stratified Study | Danish Pain Research Center | January 15, 2019 | Recruiting | N/A |
| NCT03865953 | A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain | Lateral Pharma Pty Ltd | April 9, 2019 | Completed May 3, 2020 | Primary efficacy analysis: no statistically significant difference to placebo |
| NCT03901352 | An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension | Daiichi Sankyo Co., Ltd. | March 12, 2019 | Completed December 28, 2020 | Not reported |
| NCT03928093 | A Double-blind, Randomized, Cross-over, Feasibility Trial of Pregabalin for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-associated Neuropathic Pain and Itch | The Hospital for Sick Children | August 7, 2019 | Recruiting (patients up to 40 years) | N/A |
| NCT03941834 | BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuraligia | Biohaven Pharmaceuticals, Inc. | June 25, 2019 | Recruiting | N/A |
| NCT03942848 | Assessment of Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic Pain Due to Spinal Cord Lesions. | Hospices Civils de Lyon | June 20, 2019 | Unknown | Not reported |
| NCT04054024 | A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia | Danish Headache Center | October 28, 2019 | Unknown | Not reported |
| NCT04057456 | Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury | Lawson Health Research Institute |  | Not yet recruiting | N/A |
| NCT04094662 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain | Daiichi Sankyo Co., Ltd. | September 18, 2019 | Active, not recruiting | Not reported |
| NCT04145310 | A Prospective, Single-Center, Double-Blind, Placebo-Controlled Trial of BOL-DP-o-04 in Patients With Low Back Pain and Sciatica | Breath of Life International Pharma Ltd | November 27, 2018 | Active, not recruiting | Not reported |
| NCT04146896 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Aptinyx | November 12, 2019 | Active, not recruiting | Not reported |
| NCT04148573 | Randomized, Double-blind, Placebo Controlled, Parallel, Multicentric, Phase IIa Clinical Trial to Evaluate Safety, Tolerability, Therapeutic Efficacy of Daily Oral Treatment NFX88 on Neuropathic Pain in Patients With Spinal Cord Injury | Neurofix S.L. | October 1, 2019 | Active, not recruiting | Not reported |
| NCT04238793 | A Phase 1/2a, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Therapeutic Activity of Single Ascending Doses of KLS-2031 Administered by Transforaminal Epidural Injection in Patients With Neuropathic Pain From Lumbosacral Radiculopathy | Kolon Life Science | March 10, 2020 | Recruiting | N/A |
| NCT04276727 | A Phase II RCT of Topical Menthol Gel Versus Placebo in the Treatment of Chemotherapy Induced Peripheral Neuropathic Pain | University of Edinburgh | November 4, 2019 | Recruiting | N/A |
| NCT04379011 | Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Pilot Clinical Trial | University of Minnesota | February 1, 2021 | Recruiting | N/A |
| NCT04429919 | A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain | Algiax Pharmaceuticals GmbH | June 22, 2020 | Recruiting | N/A |
| NCT04431778 | Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain | University Hospital, Clermont-Ferrand | November 6, 2020 | Recruiting | N/A |
| NCT04455633 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain | Lexicon Pharmaceuticals | July 7, 2020 | Recruiting | N/A |
| NCT04476108 | Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain | Eli Lilly and Company | July 15, 2020 | Completed November 11, 2021 | Not reported |
| NCT04480164 | A Randomized Double-blind Ascending-dose Placebo-controlled Study of N-desmethylclobazam in Patients With Peripheral Neuropathic Pain | University Hospital, Geneva | June 24, 2020 | Recruiting | N/A |
| NCT04603066 | Administration of Ondansetron With P-glycoprotein Inhibitor Tariquidar in Patients With Neuropathic Pain | Washington University School of Medicine | January 31, 2021 | Recruiting | N/A |
| NCT04641273 | A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain | Bayer | January 22, 2021 | Recruiting | N/A |
| NCT04647773 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Pregabalin Capsule-Controlled, 13-Week, Adaptive-design Phase 2/3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Diabetic Peripheral Neuropathic Pain | Haisco Pharmaceutical Group Co., Ltd. |  | Not yet recruiting | N/A |
| NCT04647877 | Enrichment Randomized Double-blind, Placebo-controlled Cross-over Trial With PHEnytoin Cream in Patients With Painful Chronic Idiopathic Axonal polyNEuropathy | UMC Utrecht | September 17, 2020 | Recruiting | N/A |
| NCT04662281 | A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1) | Lexicon Pharmaceuticals | December 29, 2020 | Recruiting | N/A |
| NCT04666714 | National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain | EMS |  | Not yet recruiting | N/A |
| NCT04679545 | A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet | Pure Green | December 10, 2020 | Recruiting | N/A |
| NCT04688671 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain | Eliem Therapeutics (UK) Ltd. | November 9, 2020 | Recruiting | N/A |
| NCT04707157 | Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain | Eli Lilly and Company | May 6, 2021 | Recruiting | N/A |
| NCT04930887 | Prospective, Randomized, Double-blinded, Placebo-controlled, Cross-over Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) Towards the Ipsilateral Pterygopalatine Fossa for the Treatment of Craniofacial Pain | Stanford University |  | Not yet recruiting | N/A |
| NCT05000658 | Efficacy of Soluble Dexamethasone by Echo-guided Infiltration Through the Sacrococcygeal Hiatus in Refractory Sciatica: a Prospective Randomised Double-blind Study Versus Placebo | Nantes University Hospital |  | Not yet recruiting | N/A |
| NCT05140863 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia | Haisco Pharmaceutical Group Co., Ltd. | November 1, 2021 | Recruiting | N/A |
| NCT05177094 | A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain | Eli Lilly and Company | January 26, 2022 | Recruiting | N/A |
| NCT05206773 | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naïve or Untreated for at Least 6 Months | Genzyme, a Sanofi Company |  | Not yet recruiting | N/A |
| NCT05217628 | A Phase II/III, Multicentre, 8-week run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, With a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients With Pain Associated With Trigeminal Neuralgia With Suboptimal Response to Their Current Anti-pain Therapy. | Noema Pharma AG | January 11, 2022 | Recruiting | N/A |
| NCT05219812 | A Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Phase 2a Study to Assess the Safety and Signal in Efficacy of BAY 2395840 in Patients With Diabetic Neuropathic Pain | Bayer | January 31, 2022 | Not yet recruiting | N/A |
| NCT05235191 | A Randomized Controlled Trial Study to Assess the Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies | University of Sao Paulo | September 6, 2019 | Recruiting | N/A |

Search with ‘neuropathic pain’, ‘adult’, ‘older adult’, ‘interventional’, ‘phase 2 and 3’, ‘start date 2012-01-01 to 2022-02-21’ resulted in 183 trials; this database was then searched for randomised placebo-controlled trials.

1 Morel V, et al. Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients. PLos One. 11, e0152741 (2016)

2 [Zakrzewska](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Zakrzewska+JM&cauthor_id=28216232) JM, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 16, 291-300 (2017).

3 Bishoff JM, et al. A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. PLoS One. 9(10):e109144 (2014).

4 Markman J, et al. Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. J Neurol. 265, 2815-2824 (2018).

5 Jain SM, et al. Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function. Pain. 163, e738-e747 (2022).

6 Palladini M, et al. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial. Curr Med Res Opin. 35, 757-766 (2019).

7 Jiang J, et al. Effect of pregabalin on radiotherapy-related neuropathic pain in patients with head and neck cancer: a randomized controlled trial. J Clin Oncol. 37, 135-143 (2019).

8 Khan JS, et al. Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial. J Pain. 20, 980-993 (2019)**.**

9 Kato J, et al. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies. Clin Ther. 43, 822-835.E16 (2021).

10 Kersten C, et al. Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial. Pain Med. 20, 2495-2505 (2019).

11 Pickering G, et al. Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery: a randomized, double-blind controlled trial. Pain. 160, 1186-1195 (2019).

12 Bouhassira D, et al. Safety and efficacy of an equimolar mixture of oxygen and nitrous oxide: a randomized controlled trial in patients with peripheral neuropathic pain. Pain. 162, 1104-1115 (2021).

13 Rice AS, et al. [Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. Pain. 162, 2578-2589 (2021).](https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFRcgF8cRFjA6h9Ei4L3BUgWwNG0it.)

14 Lipone P, et al. Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study. CNS Drugs. 34, 1177-1189 (2020).